Zacks Research Has Pessimistic View of Sanofi Q1 Earnings

Key Points

• Zacks Research has revised its Q1 2027 earnings estimate for Sanofi down to $1.12 per share, from a prior estimate of $1.13, reflecting a cautious outlook.
• Despite the downgrade, analysts display mixed reactions, with Morgan Stanley and JPMorgan upgrading their ratings to "overweight", while maintaining a consensus target price of $62.67.
• Sanofi's recent earnings report showed a missed EPS estimate of $0.90, alongside a revenue decline of 7.0% year-over-year, raising concerns over its financial performance.

Sanofi (NASDAQ:SNY - Free Report) - Equities researchers at Zacks Research lowered their Q1 2027 earnings estimates for shares of Sanofi in a research note issued to investors on Friday, October 10th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.12 for the quarter, down from their previous forecast of $1.13. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi's Q2 2027 earnings at $1.18 EPS and FY2027 earnings at $5.03 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period in the prior year, the business earned $1.73 EPS. Sanofi's quarterly revenue was down 7.0% compared to the same quarter last year.

Several other equities research analysts have also issued reports on the stock. Morgan Stanley upgraded shares of Sanofi from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Weiss Ratings restated a "hold (c)" rating on shares of Sanofi in a research note on Wednesday, October 8th. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Barclays restated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $62.67.

Sanofi Price Performance

Sanofi stock opened at $48.09 on Monday. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company's 50 day moving average price is $48.27 and its two-hundred day moving average price is $49.75. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The stock has a market cap of $118.09 billion, a P/E ratio of 11.56, a P/E/G ratio of 1.17 and a beta of 0.51.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SNY. Ameritas Advisory Services LLC purchased a new position in shares of Sanofi during the 2nd quarter valued at $28,000. Accent Capital Management LLC purchased a new position in shares of Sanofi during the 1st quarter valued at $29,000. Eastern Bank grew its position in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Sanofi during the 1st quarter worth $33,000. Finally, Golden State Wealth Management LLC lifted its holdings in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after acquiring an additional 545 shares during the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.